ARWR

Business Context and Reporting Period

Company: Arrowhead Research Corporation (a development-stage nanotechnology holding company)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: Arrowhead operates through majority-owned subsidiaries Unidym (carbon nanotube electronics) and Calando (RNAi therapeutics), wholly-owned subsidiaries Tego and Agonn, and minority investments in Nanotope and Leonardo Biosystems. The company is executing a cash conservation strategy, shifting from internal development to licensing and partnering models due to capital constraints.

Key Financial Metrics

Note: Revenue for the three months ended June 30, 2009, included $1.75 million in license fees from Calando and $684,531 in inventory sales. Operating expenses included a non-cash charge of $1.66 million for purchased in-process R&D related to Unidym stock acquisitions.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased significantly from $235,372 in the prior year quarter to $2,633,191, driven primarily by a $2.4 million licensing agreement with Cerulean Pharma for Calando's drug delivery platform.
• Expense Reduction: Operating expenses decreased by approximately 51% (from $10.1 million to $5.0 million) compared to the prior year quarter, reflecting staff reductions, facility closures (Unidym Texas, Calando Pasadena), and reduced clinical trial spending.
• Loss Reduction: Net loss improved from $7.5 million in the prior year quarter to $2.5 million, largely due to the aforementioned expense cuts.
• Liquidity Decline: Cash and cash equivalents dropped from $10.1 million at September 30, 2008, to $1.9 million at June 30, 2009, a decrease of over $8 million during the nine-month period.

Guidance, Outlook, and Risks

Management Commentary & Strategy: Management has adopted a strict cash conservation strategy. Unidym is transitioning from manufacturing to a licensing/partnering model for CNT production (partnering with Continental Carbon). Calando has closed its laboratory and is seeking partners for its siRNA clinical program. The company expects to continue reducing cash burn in the fourth quarter of fiscal 2009.

Going Concern: The filing explicitly states that the company's operating losses and negative cash flows raise substantial doubt about its ability to continue as a going concern for the next 12 months without additional capital. The company requires further financing to meet operating needs for fiscal 2010.

Subsequent Events: Following the period end, the company completed a private placement raising approximately $2.76 million (9.2 million units at $0.30/unit). Additionally, the CFO resigned effective August 10, 2009, with a former executive named interim CFO.

Key Risks:

• Capital Constraints: Insufficient cash reserves to fund current operations; failure to raise capital could force cessation of operations.
• Intellectual Property: Unidym's critical Rice University license includes an insolvency provision; failure to meet solvency tests could terminate the license.
• Market Acceptance: Commercial viability of nanotechnology products remains unproven.
• Delisting Risk: Stock price and equity levels pose risks to maintaining NASDAQ listing status.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.9 million cash balance plus the $2.76 million subsequent financing against the projected burn rate for fiscal 2010.
• Unidym Solvency: Confirm Unidym's compliance with the Rice University license solvency covenants to prevent IP termination.
• Calando Milestones: Monitor the status of the Cerulean Pharma agreement and the potential for future milestone payments versus the risk of the deal failing to progress.
• Debt Obligations: Review the terms of the $500,000 Calando convertible note and Unidym's capital lease obligations ($979k total) to assess immediate repayment risks.
• Management Stability: Assess the impact of the CFO resignation and the transition to an interim CFO on financial reporting and strategic execution.